Physician profile
Anwar Iqbal
NPI 1174856090
$545.14
in general payments reported to CMS, 2019-2025
11 companies · $20.50 in 2025
The $20.50 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $11.96 · 2021: $65.42 · 2022: $17.99 · 2023: $95.61 · 2024: $9.24 · 2025: $20.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110 · Education: $14.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.37 |
| Education | $14.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $145.38 | 2019 | |
| Fresenius USA Marketing, INC. | $125.71 | 2019-2023 | Velphoro |
| Astrazeneca Pharmaceuticals Lp | $62.04 | 2019-2022 | |
| Gilead Sciences, INC. | $42.95 | 2021 | |
| Akebia Therapeutics INC | $39.81 | 2021-2023 | Auryxia |
| Vifor Pharma, INC. | $33.11 | 2019 | |
| Mallinckrodt Enterprises LLC | $28.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.54 | 2019 | |
| Novo Nordisk INC | $20.50 | 2025 | Rybelsus, Ozempic |
| Travere Therapeutics, INC. | $14.98 | 2023-2024 | |
| Strongbridge US INC. | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.